We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Personalized Integrative Oncology: Targeted Approaches for Optimal Outcomes: The 11th International Conference of the Society for Integrative Oncology.
- Authors
Lee, Richard T; Yang, Peiying; Greenlee, Heather; Bauer-Wu, Susan; Balneaves, Lynda G.; Zick, Suzanna; Hassona, M. D. H; Ammar, A. E.; Gao, T. Y.; Chin, M. Y.; Abdualkader, A. M.; Alaama, M.; Merzouk, A.; Ghawi, A. M.; Kucuk, O.; Guns, E. S.; Bauml, Joshua; Xie, Sharon X.; Farrar, John T.; Bowman, Marjorie A.
- Abstract
The 11th International Conference of the Society for Integrative Oncology (SIO) brought together more than 300 clinicians, researchers, patients, and advocates to hear and interact with world-leading experts about the latest research in the areas of nutrition, exercise, acupuncture, health services research, meditation, and other integrative disciplines. The conference theme, “Personalized Integrative Oncology: Targeted Approaches for Optimal Outcomes,” highlighted innovations in personalized medicine and ways this growing field will advance the evolution of individualized integrative cancer care to the next level. This year’s conference also featured a clinical track focusing on clinical information for the practicing health care professional. The conference’s rigorous schedule included 3 keynotes, 4 plenary sessions, 2 interdisciplinary tumor boards, 5 workshops, 45 concurrent oral sessions, and 106 posters. In addition to the conference theme, keynote and plenary sessions presented topics on stress and cancer, the importance of sleep for cancer patients, epigenetic mechanisms of lifestyle and natural products, recently published Journal of the National Cancer Institute monograph on integrative oncology, SIO’s clinical practice guidelines for breast cancer survivors, and a joint session of the American Academy of Hospice and Palliative Medicine and SIO about supportive care and symptom management. This highly successful conference helped further the mission of the SIO to advance evidence-based, comprehensive, integrative health care to improve the lives of people affected by cancer.Abstract 12In Vivo Assessment of the Therapeutic Effects of Lyophilized Leech Saliva Extract From Hirudinaria manillensis on Different Tumor Xenograft Models in Nude MiceBackground: Ancient traditional physicians from many countries used leeching to treat a wide range of diseases for thousands of years. A large number of peptides and proteins have been identified and characterized in leech saliva extract (LSE), including antithrombotic agents, cancer metastasis inhibitors, and antimicrobials. Currently, leech therapy is established as an important tool in microsurgery, and reconstructive operations having demonstrated superior clinical outcomes for the optimal salvage of grafted tissues. Methods: In the current study, we have determined the in vivo toxicity and efficacy of LSE from Hirudinaria manillensis. For the toxicity study, we used 5 groups of CD1 mice, 3 mice per group, which were subcutaneously injected with vehicle or 1, 5, 10, and 20 mg/kg of LSE twice weekly for 4 weeks. After 4 weeks, we collected blood samples for complete blood count as well as liver and kidney function tests. In addition, liver, spleen, kidney, lung, and brain tissues were collected for further toxicological analysis (ongoing). To evaluate the in vivo efficacy of LSE in the PC3 tumor model, we used 4 groups of male nude mice, 6 mice per group, which were subcutaneously injected with 0.5 mg/kg or 1 mg/kg LSE, docetaxel (15 mg/kg) as a positive control or vehicle, respectively. Currently, we are determining the effect of LSE on the LNCaP xenograft mouse model (ongoing study). Results: The data demonstrate that LSE is safe when administered up to 20 mg/kg with no toxicity. There is a significant decrease in the growth of PC3 xenografts with either docetaxel or LSE (1 mg/kg) treatment compared to the vehicle-treated control mice. There was no significant difference between the antitumor activity of docetaxel and LSE (1 mg/kg). There was a significant decrease in the body weight of docetaxel-treated mice while there was no change in the body weight of LSE-treated mice. Conclusions: To our knowledge this is the first report of LSE as a safe biological agent with significant antitumor activity in the PC3 prostate cancer xenograft model with no apparent side effects.Abstract 23Baseline Response Expectancy: A Potential Tool for ...
- Subjects
ALTERNATIVE medicine; CANCER patient medical care; CONFERENCES &; conventions; HEALTH care teams; RESEARCH funding; INTEGRATIVE medicine; INDIVIDUALIZED medicine
- Publication
Integrative Cancer Therapies, 2015, Vol 14, Issue 1, p98
- ISSN
1534-7354
- Publication type
Article
- DOI
10.1177/1534735414563603